Quanterix Corporation
NGM: QTRXLive Quote
📈 ZcoreAI Score
Our AI model analyzes Quanterix Corporation's price action across multiple timeframes using regression channels and statistical scoring.
Get QTRX Z-Score →About Quanterix Corporation
Healthcare
Medical Devices
Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and sales force and distributors. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
📊 Fundamental Analysis
Quanterix Corporation demonstrates a profit margin of -77.1%, which is below the sector average, suggesting competitive pressure.
The company recently reported 24.7% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -34.2%, which indicates that capital utilization is currently under pressure.
At a current price of $3.36, QTRX currently trades near the bottom of its 52-week range (2%), indicating potential value or weakness (Range: $3.23 - $8.77).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$157.72M
Trailing P/E
--
Forward P/E
-1.76
Beta (5Y)
1.32
52W High
$8.77
52W Low
$3.23
Avg Volume
722K
Day High
Day Low